Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma

NCT00411229 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00411229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00411229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
November 30, 2012
Enrollment
1,035 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasms